We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

TIGIT/CD155 Blockade Bioassay

Measure potency and stability of biologics designed to block immune checkpoint signals

  • Prequalified according to ICH guidelines
  • 96- and 384-well plate formats
  • No primary cell culture required

Choose an option

Catalog number selected: J2201

$ 1,040.00 Your price:

Add to Cart
This product is discontinued
TIGIT/CD155 Blockade Bioassay
1 each
$ 1,040.00
Your price: Log in
Change Configuration
32454752-overview

Measure the ability of biologics to block immune checkpoint signals

TIGIT, also known as WUCAM and Vstm3, is an immune checkpoint protein expressed on lymphocytes. Highest expression levels are observed on effector CD4+ and CD8+ T cells, regulatory T cells, and NK cells. TIGIT has several distinct mechanisms of action that inhibit lymphocyte activation. First, TIGIT is an inhibitory counterpart of the co-stimulatory receptor CD226. When TIGIT is present on the surface of lymphocytes, it outcompetes CD226 for CD155 binding and thus negates CD226 signaling. Second, TIGIT inhibits CD226 homodimerization in cis, preventing CD226 signaling. Third, the cytoplasmic tail of TIGIT contains an immunoreceptor tyrosine-based inhibitory motif (ITIM), which could potentially lead to inhibitory signaling. 

The TIGIT/CD155 Blockade Bioassay reflects the mechanism of action (MOA) of biologics designed to block the TIGIT/CD155 interaction. 

32454752-assaycomponents-background

Assay Components

The assay consists of two genetically engineered cell lines:

TIGIT Effector Cells: Jurkat T cells expressing human TIGIT with a luciferase reporter driven by a native promoter that can respond to both TCR activation and CD226 co-stimulation

CD155 aAPC/CHO-K1 Cells: CHO-K1 cells engineered to express human CD155 with an engineered cell-surface protein designed to activate the TCR complex in an antigen-independent manner

When the two cell types are co-cultured, TIGIT inhibits CD226 activation and promoter-mediated luminescence. Addition of an anti-TIGIT antibody blocks the interaction of TIGIT with CD155 or inhibits the ability of TIGIT to prevent CD226 homodimerization, resulting in promoter-mediated luminescence. 

The Workflow

Traditional Method

12052MA-W-a

'Cells as reagents' Method

12052MA-W-b

Standardized Reagents Improve Results

  • Thaw-and-use cell format provides significant time and labor savings over traditional methods while reducing variability.
  • Kit includes all of the required reagents in standardized formats.
  • Easily amenable to high-throughput workflows.

The Assay Principle

The TIGIT/CD155 Blockade Bioassay is a bioluminescent cell-based assay that overcomes the limitations of existing assays and can be used to measure the potency and stability of antibodies and other biologics targeting TIGIT.

14857ma-w
Representation of the TIGIT/CD155 Blockade Bioassay. The bioassay consists of two genetically engineered cell lines, TIGIT Effector Cells and CD155 aAPC/CHO-K1 Cells. Panel A. When co-cultured, TIGIT inhibits CD226 pathway-activated luminescence. The addition of anti-TIGIT antibody blocks the TIGIT/CD155 interaction, thereby re-establishing CD226 pathway-activated luminescence, which can be detected in a dose-dependent manner by addition fo BIo-Glo™ Reagent and quantitation with a luminometer. Panel B. When co-cultured with non-TIGIT-expressing Effector Cells, CD155 induces luminescence by activation of the CD226 pathway. 

Assay Performance Data

Accuracy and Precision are critical to bioassays and the development of biologics. The TIGIT/CD155 Blockade Bioassay is both accurate and precise. Accuracy is a measure of how close results are to a target or reference value. Precision is a measure of repeatability. This assay was developed and prequalified according to ICH guidelines for accuracy and precision giving it the performance characteristics required for many applications of a bioassay used for antibody drug discovery research and development.

Accuracy for Assay Performance Data
Accurate, but not precise

Accuracy
Measure of ability to replicated a reference or "target" value.
IntraLab Precision
Precise, but not accurate

IntraLab Precision

Measure of repeatability from multiple assays of the same homogeneous sample under the same operating conditions over a short time (same analyst; same lab; same day).

Intermediate Precision Data Target 3
Accurate and precise

Intermediate Precision

Measure of repeatability of multiple assays of the same homogeneous sample with different analysts or equipment or on different days.

32454752-data-linear
Linear

Linearity

Ability of your assay to provide measured values that are proportional to the concentration of the sample.

Accuracy

Expected Relative Potency Recovery
50% 101.8%
70% 102.8%
140% 101.0%
200% 98.5%

Repeatability (100% reference, %CV)

11.0%

Intermediate Precision (%CV)

9.7%

Linearity

r 2 = 0.999 (50-200% range)
y = 0.974x + 3.33


The TIGIT/CD155 Blockade Bioassay reflects the mechanism of action (MOA) and specificity of biologics designed to block the TIGIT/CD155 interaction.

The TIGIT/CD155 Blockade Bioassay measures the activity of Control Ab, Anti-TIGIT.

14858ma-w
TIGIT Effector Cells were incubated with CD155 aAPC/CHO-K1 Cells in the presence of a serial titration of Control Ab, Anti-TIGIT (Cat.# J2051), anti-PD-1 (nivolumab), anti-CTLA-4 (ipilimumab) or anti-PD-L1 blocking Abs as indicated. 
14923ma-w
TIGIT Effector Cells were plated overnight. The following day, a titration fo Control Ab, Anti-TIGIT, was added followed by CD155 aAPC/CHO-K1 Cells.
32454752-related-products-background

Product Kit Formats and Related Products

  • Kits are available in 1X and 5X sizes.
  • Control Ab, Anti-TIGIT, is available separately.

Specifications

You are viewing: J2201 Change Configuration

What's in the box?

Item Part # Size

TIGIT Effector Cells

J169A 1 × 1 vial

CD155 aAPC/CHO-K1 Cells

J180A 1 × 1 vial

Fetal Bovine Serum

J121A 1 × 4ml

Bio-Glo™ Luciferase Assay Buffer

G719A 2 × 10ml

Bio-Glo™ Luciferase Assay Substrate

G720A 2 × 1 vial

RPMI 1640 Medium

G708A 1 × 36ml

SDS

Choose language:

Certificate of Analysis

See all certificates for J2201 Search
View more results
No results
Loading…

Use Restrictions

Not For Medical Diagnostic Use.

Patents and Disclaimers

NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use” means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega’s. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

U.S. Pat. No. 8,008,006 and European Pat. No. 1341808.

Patent Pending.

Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.

Product cannot be used for proficiency testing.

Specifications

You are viewing: J2205 Change Configuration

What's in the box?

Item Part # Size

TIGIT Effector Cells

J169A 5 × 1 vial

CD155 aAPC/CHO-K1 Cells

J180A 5 × 1 vial

Fetal Bovine Serum

J121A 5 × 4ml

Bio-Glo™ Luciferase Assay Buffer

G719A 10 × 10ml

Bio-Glo™ Luciferase Assay Substrate

G720A 10 × 1 vial

RPMI 1640 Medium

G708A 5 × 36ml

SDS

Choose language:

Certificate of Analysis

See all certificates for J2205 Search
View more results
No results
Loading…

Use Restrictions

Not For Medical Diagnostic Use.

Patents and Disclaimers

NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use” means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega’s. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

Patent Pending.

U.S. Pat. No. 8,008,006 and European Pat. No. 1341808.

Product cannot be used for proficiency testing.

Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.

Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom